Litcius/Paper detail

Topical antimicrobial peptide omiganan recovers cutaneous dysbiosis but does not improve clinical symptoms in patients with mild to moderate atopic dermatitis in a phase 2 randomized controlled trial

Tessa Niemeyer‐van der Kolk, Thomas P. Buters, Lara Krouwels, Jiry Boltjes, Marieke L. de Kam, Hein van der Wall, Dirk C.J.G. van Alewijk, Ellen H. A. van den Munckhof, Martin Becker, Gary Feiss, Edwin F. Florencia, Errol P. Prens, Matthijs Moerland, Jacobus Burggraaf, Robert Rißmann, Martijn B. A. van Doorn

2020Journal of the American Academy of Dermatology44 citationsDOIOpen Access PDF

Topics & Concepts

MedicineTolerabilityAtopic dermatitisDysbiosisStaphylococcus aureusRandomized controlled trialAntimicrobialClinical trialEczema Area and Severity IndexMicrobiomeInternal medicinePharmacodynamicsDermatologyGastroenterologyAdverse effectMicrobiologyPharmacokineticsDiseaseBioinformaticsBacteriaBiologyGeneticsDermatology and Skin DiseasesAntimicrobial Peptides and ActivitiesProbiotics and Fermented Foods
Topical antimicrobial peptide omiganan recovers cutaneous dysbiosis but does not improve clinical symptoms in patients with mild to moderate atopic dermatitis in a phase 2 randomized controlled trial | Litcius